Evidence map›Paper›PMID 36597527›Full record

ArticlebioRxiv : the preprint server for biology2022

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

Payton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S Arunachalam, Mengyun Hu, Ozan S Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 16 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Payton A-B WeidenbacherSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Mrinmoy SanyalSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Natalia FriedlandSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Shaogeng TangSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Prabhu S ArunachalamInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Mengyun HuInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Ozan S KumruVaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.
Mary Kate MorrisCalifornia Department of Public Health, Richmond, CA, USA.
Jane FontenotNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
Lisa ShirreffNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
Jonathan DoSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Ya-Chen ChengSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Gayathri VasudevanIAVI, New York, NY, USA.
Mark B FeinbergIAVI, New York, NY, USA.
Francois J VillingerNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
Carl HansonCalifornia Department of Public Health, Richmond, CA, USA.
Sangeeta B JoshiVaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.
David B VolkinVaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.
Bali PulendranInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Peter S KimSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Stanford University · USUniversity of Kansas · USUniversity of Louisiana at Lafayette · USCalifornia Department of Public Health · USInternational AIDS Vaccine Initiative · USChan Zuckerberg Initiative (United States) · US

Funding

The Stanford-SLAC CryoEM Center supplementU24GM129541 · NIGMS · STANFORD UNIVERSITY · PI CHIU, WAH, HEDMAN, BRITT · 2018 to 2023
$54.8M
Systems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI Holden T. Maecker · 2022 to 2026
$13.2M
Creating high-resolution, epitope-focused vaccinesDP1AI158125 · NIAID · STANFORD UNIVERSITY · PI KIM, PETER S · 2020 to 2024
$5.9M
Cell Surface Receptor Recognition and Membrane Fusion in Mammalian FertilizationK99HD104924 · NICHD · STANFORD UNIVERSITY · PI TANG, SHAOGENG · 2021 to 2022
$383k
NIAID NIH HHS DP1 AI158125NIAID NIH HHS U19 AI167903NICHD NIH HHS K99 HD104924NIGMS NIH HHS U24 GM129541
6 · The paper itself

Abstract

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ∼one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly booster vaccine, and as a primary vaccine for pediatric use including in infants.

Identifiers

PMID36597527
PMCPMC9810210
OpenAlexW4312198366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.